The Wnt signaling pathway in bipolar disorder

Neuroscientist

Volumn 8, Issue 5, 2002, Pages 497-511

  Gould, Todd D ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar disorder; Circadian rhythms; Glycogen synthase kinase; Lithium; Neuroprotection; Valproic acid; Wnt signaling

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; THAPSIGARGIN; VALPROIC ACID; WNT PROTEIN;

ANIMAL CELL; CELL SURVIVAL; CIRCADIAN RHYTHM; CONTROLLED STUDY; EMBRYO DEVELOPMENT; HUMAN; HUMAN CELL; MANIC DEPRESSIVE PSYCHOSIS; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036788036     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385802237176     Document Type: Review

References (143)

1. Ali A, Hoeflich KP, Woodgett JR. 2001. Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 101:2527-40.
2. Angst J, Sellaro R. 2000. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 48:445-57.
3. Arendt T, Lehmann K, Seeger G, Gartner U. 1999. Synergistic effects of tetrahydroaminoacridine and lithium on cholinergic function after excitotoxic basal forebrain lesions in rat. Pharmacopsychiatry 32:242-7.
4. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, and others. 2001. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 302:117-20.
5. Begley CE, Annegers JF, Swann AC, Lewis C, Coan S, Schnapp WB, and others. 2001. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 19:483-95.
6. Berridge MJ, Downes CP, Hanley MR. 1982. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 206:587-95.
7. Berridge MJ, Downes CP, Hanley MR. 1989. Neural and developmental actions of lithium: a unifying hypothesis. Cell 59:411-9.
8. Bijur GN, De Sarno P, Jope RS. 2000. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 275:7583-90.
9. Bordonaro M, Mariadason JM, Aslam F, Heerdt BG, Augenlicht LH. 1999. Butyrate-induced apoptotic cascade in colonic carcinoma cells: modulation of the beta-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin. Cell Growth Differ 10:713-20.
10. Bowden CL. 1997. Toward an integrated biological model of bipolar disorder. In: Young LT, Joffe RT, editors. Bipolar disorder: biological models and their clinical application. New York: Marcel Dekker. p 235-54.
11. Bruno V, Sortino MA, Scapagnini U, Nicoletti F, Canonico PL. 1995. Antidegenerative effects of Mg(2+)-valproate in cultured cerebellar neurons. Funct Neurol 10:121-30.
12. Cadigan KM, Nusse R. 1997. Wnt signaling: a common theme in animal development. Genes Dev 11:3286-305.
13. Chalecka-Franaszek E, Chuang DM. 1999. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96:8745-50.
14. Chen G, Huang LD, Jiang YM, Manji HK. 1999. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72:1327-30.
15. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. 1994. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 63:2361-4.
16. Chen G, Yuan P, Hawver DB, Potter WZ, Manji HK. 1997. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 16:238-45.
17. Chen RH, Ding WV, McCormick F. 2000. Wnt signaling to betacatenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem 275:17894-9.
18. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, and others. 2001. Wnt-1 signaling inhibits apoptosis by activating betacatenin/T cell factor-mediated transcription. J Cell Biol 152:87-96.
19. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, and others. 2002. Neuroprotective effects of lithium in cultured cells and animal models of disease. Bipolar Disord 4:129-36.
20. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, and others. 2000. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7:793-803.
21. Cotter D, Kerwin R, al-Sarraji S, Brion JP, Chadwich A, Lovestone S, and others. 1998. Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental abnormality. Neuroreport 9:1379-83.
22. Craddock N, Jones I. 1999. Genetics of bipolar disorder. J Med Genet 36:585-94.
23. Craddock N, Jones I. 2001. Molecular genetics of bipolar disorder. Br J Psychiatry 178:S128-33.
24. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. 2001. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 77:94-102.
25. Crowder RJ, Freeman RS. 2000. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 275:34266-71.
26. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, and others. 1999. Tryptophan -depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46:212-20.
27. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, and others. 2001. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20:252-9.
28. Drevets WC. 2000a. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 126:413-31.
29. Drevets WC. 2000b. Neuroimaging studies of mood disorders. Biol Psychiatry 48:813-29.
30. Drevets WC, Gadde K, Krishnan R. 1999. Neuroimaging studies of depression. In: Charney DS, Nester EJ, Bunney BS, editors. Neurobiology of mental illness. New York: Oxford University Press. p 394-418.
31. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME. 1997. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386:824-7.
32. Eldar-Finkelman H, Seger R, Vandenheede JR, Krebs EG. 1995. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J Biol Chem 270:987-90.
33. Emily-Fenouil F, Ghiglione C, Lhomond G, Lepage T, Gache C. 1998. GSK3beta/shaggy mediates patterning along the animal-vegetal axis of the sea urchin embryo. Development 125:2489-98.
34. Garlow SJ, Musselman DL, Nemeroff CB. 1999. The neurochemistry of mood disorders clinical studies. In: Charney DS, Nester EJ, Bunney BS, editors. Neurobiology of mental illness. New York: Oxford University Press. p 348-64.
35. Goodwin FK, Jamison KR. 1990. Manic-depressive illness. New York: Oxford University Press.
36. Gould TD, Manji HK. 2002. Signaling networks in the pathophysiology and treatment of mood disorders. J Pyschosom Res 53:687-95.
37. Grimes AC, Jope RS. 2001. CREB DNA binding activity is inhibited by glycogen synthase kinase-3beta and facilitated by lithium. J Neurochem 78:1-15.
38. Hall AC, Lucas FR, Salinas PC. 2000. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 100:525-35.
39. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, and others. 1995. The molecular basis of Turcot's syndrome. N Engl J Med 332:839-47.
40. Harwood AJ. 2001. Regulation of GSK-3: a cellular multiprocessor. Cell 105:821-4.
41. Harwood AJ, Plyte SE, Woodgett J, Strutt H, Kay RR. 1995. Glycogen synthase kinase 3 regulates cell fate in Dictyostelium. Cell 80:139-48.
42. Healy D, Waterhouse JM. 1995. The circadian system and the therapeutics of the affective disorders. Pharmacol Ther 65:241-63.
43. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. 1997. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 185:82-91.
44. Hedgepeth CM, Deardorff MA, Rankin K, Klein PS. 1999. Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin. Mol Cell Biol 19:7147-57.
45. Hetman M, Cavanaugh JE, Kimelman D, Xia Z. 2000. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 20:2567-74.
46. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, Kleihues P, and others. 2000. APC mutations in sporadic medulloblastomas. Am J Pathol 156:433-7.
47. Ikonomov OC, Manji HK. 1999. Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry 156:1506-14.
48. Jamison KR. 1986. Suicide and bipolar disorders. Ann N Y Acad Sci 487:301-15.
49. Jope RS. 1999. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 4:117-28.
50. Jope RS, Bijur GN. 2002. Mood stabilizers, glycogen synthase kinase3beta and cell survival. Mol Psychiatry 7(Suppl 1):S35-45.
51. Jope RS, Williams MB. 1994. Lithium and brain signal transduction systems. Biochem Pharmacol 47:429-41.
52. Kao KR, Elinson RP. 1988. The entire mesodermal mantle behaves as Spemann's organizer in dorsoanterior enhanced Xenopus laevis embryos. Dev Biol 127:64-77.
53. Kasper S, Wehr TA. 1992. The role of sleep and wakefulness in the genesis of depression and mania. Encephale 18(Spec No 1):45-50.
54. Kleijn M, Proud CG. 2000. The activation of eukaryotic initiation factor (eIF)2B by growth factors in PC12 cells requires MEK/ERK signalling. FEBS Lett 476:262-5.
55. Klein PS, Melton DA. 1996. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93:8455-9.
56. Klemfuss H. 1992. Rhythms and the pharmacology of lithium. Pharmacol Ther 56:53-78.
57. Koch A, Waha A, Tonn JC, Sorensen N, Berthold F, Wolter M, and others. 2001. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93:445-9.
58. Kozlovsky N, Belmaker RH, Agam G. 2000. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 157:831-3.
59. Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT. 2000. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 16:279-83.
60. Lenox RH, Gould TD, Manji HK. 2002. Endophenotypes in bipolar disorder. Am J Med Genet 114:391-406.
61. Lenox RH, McNamara RK, Watterson JM, Watson DG. 1996. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 57:23-31; discussion 32-3.
62. Lesort M, Greendorfer A, Stockmeier C, Johnson GV, Jope RS. 1999. Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain. J Neural Transm 106:1217-22.
63. Li X, Bijur GN, Jope RS. 2002. Glycogen synthase kinase 3-beta, mood stabilizers, and neuroprotection. Bipolar Disord 4:137-44.
64. Lowrey PL, Shimomura K, Antoch MP, Yamazaki S, Zemenides PD, Ralph MR, and others. 2000. Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau. Science 288:483-92.
65. Lucas FR, Goold RG, Gordon-Weeks PR, Salinas PC. 1998. Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci 111:1351-61.
66. Lucas FR, Salinas PC. 1997. WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev Biol 192:31-44.
67. Maeda Y. 1970. Influence of ionic conditions on cell differentiation and morphogenesis of the cellular slime molds. Dev Growth Differ 12:217-27.
68. Maes M, Meltzer HY. 1995. The serotonergic hypothesis of depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven. p 921-32.
69. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. 1999a. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 60:27-39; discussion 40-1, 113-6.
70. Manji HK, Chen G, Hsiao JK, Risby ED, Masana MI, Potter WZ. 1996. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 57:34-46; discussion 47-8.
71. Manji HK, Duman RS. 2001. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 35:5-49.
72. Manji HK, Lenox RH. 2000. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48:518-30.
73. Manji HK, Moore GJ, Chen G. 1999b. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46:929-40.
74. Manji HK, Moore GJ, Chen G. 2000a. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 48:740-54.
75. Manji HK, Moore GJ, Rajkowska G, Chen G. 2000b. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 5:578-93.
76. Mark RJ, Ashford JW, Goodman Y, Mattson MP. 1995. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 16:187-98.
77. Martinek S, Inonog S, Manoukian AS, Young MW. 2001. A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 105:769-79.
78. McMahon AP, Moon RT. 1989. Ectopic expression of the proto-oncogene int-1 in Xenopus embryos leads to duplication of the embryonic axis. Cell 58:1075-84.
79. Miyaoka T, Seno H, Ishino H. 1999. Increased expression of Wnt-1 in schizophrenic brains. Schizophr Res 38:1-6.
80. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, and others. 1992. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1:229-33.
81. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, and others. 2000a. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 48:1-8.
82. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. 2000b. Lithium-induced increase in human brain grey matter. Lancet 356:1241-2.
83. Mora A, Gonzalez-Polo RA, Fuentes JM, Soler G, Centeno F. 1999. Different mechanisms of protection against apoptosis by valproate and Li+. Eur J Biochem 266:886-91.
84. Muller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, and others. 1992. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 86:218-22.
85. Murray CJ, Lopez AD. 1996. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274:740-3.
86. Nonaka S, Chuang DM. 1998. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9:2081-4.
87. Nonaka S, Hough CJ, Chuang DM. 1998a. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 95:2642-7.
88. Nonaka S, Katsube N, Chuang DM. 1998b. Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther 286:539-47.
89. Novak A, Dedhar S. 1999. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 56:523-37.
90. Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. 2001. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol 22:18-32.
91. Pap M, Cooper GM. 1998. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273:19929-32.
92. Pascual T, Gonzalez JL. 1995. A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Brain Res 695:289-92.
93. Patapoutian A, Reichardt LF. 2000. Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol 10:392-9.
94. Peifer M, Polakis P. 2000. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 287:1606-9.
95. Peters JM, McKay RM, McKay JP, Graff JM. 1999. Casein kinase I transduces Wnt signals. Nature 401:345-50.
96. Petronis A. 2001. Human morbid genetics revisited: relevance of epigenetics. Trends Genet 17:142-6.
97. Phiel CJ, Klein PS. 2001. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41:789-813.
98. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 25:25.
99. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR. 1992. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1114:147-62.
100. Polakis P. 2000. Wnt signaling and cancer. Genes Dev 14:1837-51.
101. Potash JB, DePaulo JR Jr. 2000. Searching high and low: a review of the genetics of bipolar disorder. Bipolar Disord 2:8-26.
102. Price JL, Blau J, Rothenfluh A, Abodeely M, Kloss B, Young MW. 1998. double-time is a novel Drosophila clock gene that regulates PERIOD protein accumulation. Cell 94:83-95.
103. Rajkowska G. In press. Cell pathology in bipolar disorder. Bipolar Disord.
104. Reifman A, Wyatt RJ. 1980. Lithium: a brake in the rising cost of mental illness. Arch Gen Psychiatry 37:385-8.
105. Reppert SM, Weaver DR. 2001. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol 63:647-76.
106. Ryves WJ, Harwood AJ. 2001. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280:720-5.
107. Sakanaka C, Leong P, Xu L, Harrison SD, Williams LT. 1999. Casein kinase iepsilon in the wnt pathway: regulation of beta-catenin function. Proc Natl Acad Sci U S A 96:12548-52.
108. Salinas PC, Hall AC. 1999. Lithium and synaptic plasticity. Bipolar Disord 1:87-90.
109. Schatzberg AF, Schildkraut JJ. 1995. Recent studies on norepinephrine systems in mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven. p 911-20.
110. Schou M. 1991. Lithium and electroconvulsive therapy: adversaries, competitors, allies? Acta Psychiatr Scand 84:435-8.
111. Sharpe C, Lawrence N, Martinez Arias A. 2001. Wnt signalling: a theme with nuclear variations. Bioessays 23:311-8.
112. Smith DG, Buffet M, Fenwick AE, Haigh D, Ife RJ, Saunders M, and others. 2001. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 11:635-9.
113. Souetre E, Salvati E, Wehr TA, Sack DA, Krebs B, Darcourt G. 1988. Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects. Am J Psychiatry 145:1133-7.
114. Staal FJ, Burgering BM, van de Wetering M, Clevers HC. 1999. Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells. Int Immunol 11:317-23.
115. Stambolic V, Ruel L, Woodgett JR. 1996. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6:1664-8.
116. Stambolic V, Woodgett JR. 1994. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 303:701-4.
117. Sutherland C, Leighton IA, Cohen P. 1993. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296:15-9.
118. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. 1993. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A 90:7789-93.
119. Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P. 1999. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3- catalysed phosphorylation of axin and beta-catenin. FEBS Lett 458:247-51.
120. Tondo L, Jamison KR, Baldessarini RJ. 1997. Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann N Y Acad Sci 836:339-51.
121. Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, Dewhurst S, and others. 2001. Activation ofglycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 13:1913-22.
122. Tsai G, Coyle JT. 1995. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 46:531-40.
123. van Gijn ME, Snel F, Cleutjens JP, Smits JF, Blankesteijn WM. 2001. Overexpression of components of the Frizzled-Dishevelled cascade results in apoptotic cell death, mediated by beta-catenin. Exp Cell Res 265:46-53.
124. Vestergaard P, Aagaard J. 1991. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 21:33-8.
125. Vielhaber E, Virshup DM. 2001. Casein kinase I: from obscurity to center stage. IUBMB Life 51:73-8.
126. Vonica A, Weng W, Gumbiner BM, Venuti JM. 2000. TCF is the nuclear effector of the beta-catenin signal that patterns the sea urchin animal-vegetal axis. Dev Biol 217:230-43.
127. Wager-Smith K, Kay SA. 2000. Circadian rhythm genetics: from flies to mice to humans. Nat Genet 26:23-7.
128. Wang J-F, Young LT, Li PP, Warsh JJ. 1997. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, editors. Bipolar disorder: biological models and their clinical application. New York: Dekker. p 41-79.
129. Wehr TA, Sack D, Rosenthal N, Duncan W, Gillin JC. 1983. Circadian rhythm disturbances in manic-depressive illness. Fed Proc 42:2809-14.
130. Wehr TA, Sack DA, Rosenthal NE. 1987. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 144:201-4.
131. Weinberger DR. 1997. The biological basis of schizophrenia: new directions. J Clin Psychiatry 58:22-7.
132. Wikramanayake AH, Huang L, Klein WH. 1998. beta-Catenin is essential for patterning the maternally specified animal-vegetal axis in the sea urchin embryo. Proc Natl Acad Sci U S A 95:9343-8.
133. Williams JA, Sehgal A. 2001. Molecular components of the circadian system in Drosophila. Annu Rev Physiol 63:729-55.
134. Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman D, Ketter TA. 2000. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 47:475-81.
135. Wirz-Justice A, Van den Hoofdakker RH. 1999. Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 46:445-53.
136. Wodarz A, Nusse R. 1998. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14:59-88.
137. Woodgett JR. 2001. Judging a protein by more than its name: gsk-3. Sci STKE RE12.
138. Wu JC, Bunney WE. 1990. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 147:14-21.
139. Yang SD, Yu JS, Lee TT, Yang CC, Ni MH, Yang YY. 1995. Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder. J Cell Biochem 59:108-16.
140. Yost C, Farr GH 3rd, Pierce SB, Ferkey DM, Chen MM, Kimelman D. 1998. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 93:1031-41.
141. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. 1996. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10:1443-54.
142. Yuan PX, Huong LD, Jiang YM, Gutkind JS, Manji HK, Chen G. 2001. The mood-stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 19:19.
143. Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL 3rd, and others. 1997. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90:181-92.